"Oxazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Six-membered heterocycles containing an oxygen and a nitrogen.
| Descriptor ID |
D010078
|
| MeSH Number(s) |
D03.383.533
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oxazines".
Below are MeSH descriptors whose meaning is more specific than "Oxazines".
This graph shows the total number of publications written about "Oxazines" by people in this website by year, and whether "Oxazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 1 | 3 |
| 2017 | 0 | 27 | 27 |
| 2018 | 1 | 36 | 37 |
| 2019 | 1 | 18 | 19 |
| 2020 | 2 | 2 | 4 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Oxazines" by people in Profiles.
-
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients. J Med Virol. 2021 12; 93(12):6557-6565.
-
CROI 2021: Advances in Antiretroviral Therapy for HIV and Antiviral Therapy for COVID-19. Top Antivir Med. 2021 Jun-Jul; 29(3):361-378.
-
Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses. Eur J Med Chem. 2021 Aug 05; 220:113467.
-
Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial. Trials. 2021 Apr 12; 22(1):270.
-
Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic. J Infect Dis. 2021 03 29; 223(6):981-984.
-
Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach. J Infect Public Health. 2020 Dec; 13(12):1856-1861.
-
COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2. J Med Virol. 2021 03; 93(3):1796-1804.
-
Highlights of AIDS 2020. Lancet HIV. 2020 08; 7(8):e532.
-
Identification of some novel oxazine substituted 9-anilinoacridines as SARS-CoV-2 inhibitors for COVID-19 by molecular docking, free energy calculation and molecular dynamics studies. J Biomol Struct Dyn. 2021 Sep; 39(15):5551-5562.
-
Cases of coronavirus disease-2019 in HIV-infected transgender women. AIDS. 2020 07 15; 34(9):1435-1436.